Prolonged survival after treatment of diffuse intrinsic pontine glioma with radiation, temozolamide, and bevacizumab: Report of 2 cases

Journal of Pediatric Hematology/Oncology

Volumn 35, Issue 1, 2013, Pages

  Aguilera, Dolly G ^a   Mazewski, Claire ^a   Hayes, Laura ^b   Jordan, Cathy ^a   Esiashivilli, Natia ^c   Janns, Anna ^a   MacDonald, Tobey J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Children's Healthcare of Atlanta ^*  (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TEMOZOLOMIDE;

ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE REPORT; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FACIAL NERVE PARALYSIS; FEMALE; HEMIPARESIS; HUMAN; HYDROCEPHALUS; HYPERTENSION; INCIDENTAL FINDING; LYMPHOCYTOPENIA; MALE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATITIS; PONTINE GLIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SCHOOL CHILD; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR VOLUME; WALKING DIFFICULTY; WEAKNESS; WOUND HEALING IMPAIRMENT;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN STEM NEOPLASMS; CHEMORADIOTHERAPY; CHILD; DACARBAZINE; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PONS; PROGNOSIS; SURVIVAL RATE;

EID: 84871791407     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318279aed8     Document Type: Article

References (20)

1. Smith MA, Freidlin B, Ries LA, et al. Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Inst. 1998;90:1269-1277.
2. Mandell LR, Kadota R, Freeman C, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group Phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys. 1999;43:959-964.
3. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466.
4. Cohen KJ, Pollack IF, Zhou T, et al. Temozolamide in the treatment of high grade gliomas in children: a report from the Children's Oncology Group. Neurol Oncol. 2011;13: 317-323.
5. Jalali R, Raut N, Arora B, et al. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2010;77:113-118.
6. Kim CY, Kim SK, Phi JH, et al. A prospective study of temozolomide plus thalidomide during and after radiation therapy for pediatric diffuse pontine gliomas: preliminary results of the Korean Society for Pediatric Neuro-Oncology study. J Neurooncol. 2010;100:193-198.
7. Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14:1131-1138.
8. Narayana A, Golfinos JG, Fischer I, et al. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys. 2008;72:383-389.
9. Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys. 2008;71: 1372-1380.
10. Kirkpatrick J, Desjardins A, Reardon D. Radiotherapy, temozolomide and bevacizumab followed by irinotecan, temozolomide and bevacizumab appears well tolerated and efficacious in newly diagnosed glioblastoma multiforme: results from a phase II study. Int J Radiat Oncol Biol Phys. 2009;75:s102-s103.
11. Sirachainan N, Pakakasama S, Visudithbhan A, et al. Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma. Neurol Oncol. 2008;10: 577-582.
12. Michalski A, Bouffet E, Taylor RE, et al. The addition of highdose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma. J Neurooncol. 2010;100:81-88.
13. Korones DN, Fisher PG, Kretschmar C, et al. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study. Pediatr Blood Cancer. 2008;50:227-230.
14. Wolff JE, Driever PH, Erdlenbruch B, et al. Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer. 2010;116:705-712.
15. Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a pediatric brain tumor consortium study. J Clin Oncol. 2010; 28:3069-3075.
16. Liu AK, Macy ME, Foreman NK. Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys. 2009;75:1148-1154.
17. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29:142-148.
18. Vredenburgh JJ, Desjardins A, Kirkpatrick JP, et al. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2010;82:58-66.
19. Maurer GD, Tritschler I, Adams B, et al. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neurol Oncol. 2009;11:747-756.
20. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28:2712-2718.